Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials.
about
Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancerRole of survival post-progression in phase III trials of systemic chemotherapy in advanced non-small-cell lung cancer: a systematic reviewBevacizumab treatment for advanced breast cancerParallel evolution under chemotherapy pressure in 29 breast cancer cell lines results in dissimilar mechanisms of resistanceIndividual-level data on the relationships of progression-free survival and post-progression survival with overall survival in patients with advanced non-squamous non-small cell lung cancer patients who received second-line chemotherapy.Progression-free survival as a potential surrogate for overall survival in metastatic breast cancer.Surrogate endpoints for overall survival in advanced non-small-cell lung cancer patients with mutations of the epidermal growth factor receptor gene.Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancerTumor-Specific Systemic Treatment in Advanced Breast Cancer - How Long does it Make Sense?Why post-progression survival and post-relapse survival are not appropriate measures of efficacy in cancer randomized clinical trials.Mesenchymal stem cells as carriers and amplifiers in CRAd delivery to tumors.In the end what matters most? A review of clinical endpoints in advanced breast cancer.Endpoints in advanced breast cancer: methodological aspects & clinical implications.US Food and Drug Administration approval overview in metastatic breast cancerLow PBRM1 identifies tumor progression and poor prognosis in breast cancer.Detecting overall survival benefit derived from survival postprogression rather than progression-free survival.The impact of data errors on the outcome of randomized clinical trials.North central cancer treatment group (NCCTG) N0537: phase II trial of VEGF-trap in patients with metastatic breast cancer previously treated with an anthracycline and/or a taxane.Which patients with metastatic breast cancer benefit from subsequent lines of treatment? An update for clinicians.Overexpression of AKIP1 predicts poor prognosis of patients with breast carcinoma and promotes cancer metastasis through Akt/GSK-3β/Snail pathwayEribulin monotherapy in patients aged 70 years and older with metastatic breast cancer.Factors affecting the association between overall survival and progression-free survival in clinical trials of first-line treatment for patients with advanced non-small cell lung cancer.Adoptive immunotherapy of metastatic breast cancer: present and future.Surrogate endpoints in second-line treatment for mCRC: a systematic literature-based analysis from 23 randomised trials.Validation of surrogate endpoints in advanced solid tumors: systematic review of statistical methods, results, and implications for policy makers.Bias in progression-free survival analysis due to intermittent assessment of progression.Combination of molecular-targeted drugs with endocrine therapy for hormone-resistant breast cancer.Overall survival (OS) endpoint: an incomplete evaluation of metastatic breast cancer (MBC) treatment outcome.Is overall survival still the primary endpoint in maintenance non-small cell lung cancer studies? An analysis of phase III randomised trials.Statistical controversies in clinical research: end points other than overall survival are vital for regulatory approval of anticancer agents.Clinical significance of post-progression survival in lung cancerRole of everolimus in the treatment of metastatic HER2-negative/HR-positive breast cancer.Post-Progression Survival Associated with Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Docetaxel Monotherapy as Second-Line Chemotherapy.Positive relationship between subsequent chemotherapy and overall survival in pancreatic cancer: meta-analysis of postprogression survival for first-line chemotherapy.A nomogram to predict survival time in women starting first-line chemotherapy for advanced breast cancer.Post-progression survival and progression-free survival in patients with advanced hepatocellular carcinoma treated by sorafenib.Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13.Factors Associated with Post-Progression Survival in Patients with Advanced Hepatocellular Carcinoma Treated with SorafenibPostprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design.Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer.
P2860
Q26829939-4CA3D657-D119-4149-8424-532634648198Q27025724-AC16F46D-F2DF-4FA0-880A-6429B0EB8FA0Q27027498-DC346B6B-E60D-4626-B5EE-0CEEDE5FFF05Q28732256-93033448-B653-4E48-B440-EEA721665D0BQ30833179-7560B344-2918-43FF-9586-023E6166C50DQ33800697-F60B060B-822A-4B7A-A00B-8999CA34B19CQ33933021-C8F3C0EA-122E-462E-B874-083CEE93813EQ34866341-A8558034-28B2-47EC-A851-6EAC9BFC545CQ34870267-89BB2296-71DF-45F8-A1C6-9F41DD8DFA53Q35164187-378837E2-0ACB-43F4-895C-DD76A57D7E6EQ35549633-8C9D2248-C56A-4C03-8B0C-9AD8EADB3FA4Q35584322-34BE0518-9191-444C-BA9C-89328F6A0DB8Q35611036-BA8BD0DE-A289-4E43-BD65-9B7FBC5722F0Q36058269-4571AF17-A7AD-4E9E-A5BB-DEDB8F58591DQ36095258-67B1421E-EDB3-4A13-BD59-328A92CB0968Q36173497-3B6CB3B5-716E-4840-A8F4-30EC132AE3E0Q36412734-E1B3F0EA-00D9-4EA0-B2BF-AC593EC700EBQ36652690-CD99C7CA-024C-466B-AEBF-8E95268A9240Q37236305-1F762C39-D076-4557-8DA8-E3FB6D382B05Q37448195-FC9382AC-3229-44D1-ABEB-0107BA370BA7Q37698199-A9597FF6-0011-4016-9242-0EBAFBE2E258Q37698439-2B6180D3-3C76-4935-BA62-640413F9A818Q38171325-83F0A206-54B9-4807-9A04-C9CEE69FF3A6Q38228850-05D3480D-54C4-40B4-9EB1-8ECB0C37FF83Q38259501-BE80CC15-5659-44D6-A895-79160D286ECDQ38277978-D058EA2C-E433-46DF-BBF2-CC05E886D6FFQ38364580-9E79927F-9666-4CD2-8249-D2EF74FA718DQ38381907-8B4E648D-E700-4503-A093-3314656871C4Q38390009-00D4B61F-C81F-47BB-B02B-AF715AC801F1Q38636718-733A28D6-F782-4717-AF34-F8C29A23C657Q38669447-547AD5A1-68AF-4D98-8BDF-35C7B679BC0BQ38690803-7BD273FB-330B-4013-A46C-882F97030479Q38852314-F75E7F60-91E2-4DB5-8182-C988FB07468AQ39150005-7682F3A4-54F3-4C81-BE25-EA5434692CB9Q39766776-F159AC7A-B22E-4A25-8469-BFDF67A84622Q40461237-E4F413D7-AB25-490B-9CC1-A98DF761CFE6Q42281334-779021C6-783D-41D2-AE8F-7954ED901CB9Q42343440-17D8AA80-FC46-47FE-8B5C-8DF4EBC6822DQ43950860-77C1CF8F-B2C7-4BC1-A2BC-1F2FFEE21DD1Q44365458-99A16FA2-7B83-44D7-8617-DA8C6C4DAA6E
P2860
Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Overall survival and post-prog ...... nt randomized clinical trials.
@en
Overall survival and post-prog ...... nt randomized clinical trials.
@nl
type
label
Overall survival and post-prog ...... nt randomized clinical trials.
@en
Overall survival and post-prog ...... nt randomized clinical trials.
@nl
prefLabel
Overall survival and post-prog ...... nt randomized clinical trials.
@en
Overall survival and post-prog ...... nt randomized clinical trials.
@nl
P356
P1476
Overall survival and post-prog ...... nt randomized clinical trials.
@en
P2093
Artur Katz
Everardo D Saad
P304
P356
10.1200/JCO.2009.25.5414
P407
P50
P577
2010-03-01T00:00:00Z